Stifel analyst Rick Wise raised the firm’s price target on Zimmer Biomet (ZBH) to $138 from $130 and keeps a Buy rating on the shares. With the stock selling near 10-year valuation lows, management recently re-emphasized that Zimmer Biomet has six major product launches underway with an increasingly visible impact as 2025 unfolds, notes the analyst, who argues that 2025 is “going to be a better year for ZBH fundamentals and therefore, the stock.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Zimmer Biomet price target lowered to $111 from $122 at Bernstein
- Zimmer Biomet price target raised to $113 from $110 at Evercore ISI
- Zimmer Biomet price target raised to $118 from $117 at Truist
- Tesla upgraded, MongoDB initiated: Wall Street’s top analyst calls